Our Basic Approach on Global Health
Despite the rapid progress in technology and knowledge of modern medicine, unmet medical needs remain in a wide range of therapeutic areas, and every R&D-based pharmaceutical company is charged with the mission of addressing these issues by creating innovative new medicines. Furthermore, there are many countries and regions where people are unable to equally access adequate medical treatment due to immature medical systems and/or poverty. We have identified "Contribution to global health," "Initiatives to improve access to medicines," and "Improvement of healthcare infrastructure in developing countries" as material issues that we pursue through our business activities. We address these issues through our R&D efforts on innovative medicines, as well as working with governments, international organizations and research institutions, and civil society.
We believe that working on establishment of healthcare systems in developing countries, training and developing human resources, and educating the public will not only contribute to achieving the SDGs, but also lead to an increase in our presence as a global pharmaceutical company.
Our Strategy in Global Health
We formulate long-term strategic plan on global health and implement our initiatives by focusing the following points.
- ● Considering the feasibility and efficiency of social implementation, we prioritize and invest our resources in infectious disease areas where we can leverage our strengths (specialty, technical capabilities, networks) and where we can synergize with our business.
- ● Recognizing that global health issues are to be addressed through global scale partnership, we work toward solving issues by developing sustainable systems in multi-platform collaboration with international organizations, government agencies, research institutions, and civil society.
- ● Referring to the designated as Least Developed Countries (LDCs)*1 defined by the United Nations or Low Income Countries (LICs)*2 defined by the World Bank, we decide the area we prioritize to address.
*2: Low Income Countries (LICs) https://data.worldbank.org/income-level/low-income
Low & Middle Income Countries (LMICs) https://data.worldbank.org/income-level/low-and-middle-income
Priorities in Addressing Global Health
Based on the "Basic Approach on Global Health" and "Our Strategy in Global Health," Sumitomo Pharma aims to support the achievement of Goal 3 of the SDGs: Good Health and Well-being. We prioritize the following four targets of Goal 3 and thereby strive to contribute to solving issues of global health.
|3.1||By 2030, reduce the global maternal mortality ratio to less than 70 per 100,000 live births||
|3.2||By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births||
|3.3||By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases||
|3.4||By 2030, reduce by one-third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being||
Please see the following section for more information.